rs111033270

Variant summary

Our verdict is Pathogenic. Variant got 10 ACMG points: 10P and 0B. PP3_ModeratePP5_Very_Strong

The NM_022124.6(CDH23):​c.5237G>A​(p.Arg1746Gln) variant causes a missense change. The variant allele was found at a frequency of 0.00016 in 1,613,864 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. R1746W) has been classified as Likely benign.

Frequency

Genomes: 𝑓 0.00014 ( 0 hom., cov: 33)
Exomes 𝑓: 0.00016 ( 0 hom. )

Consequence

CDH23
NM_022124.6 missense

Scores

3
5
9

Clinical Significance

Pathogenic criteria provided, multiple submitters, no conflicts P:16

Conservation

PhyloP100: 4.76
Variant links:
Genes affected
CDH23 (HGNC:13733): (cadherin related 23) This gene is a member of the cadherin superfamily, whose genes encode calcium dependent cell-cell adhesion glycoproteins. The encoded protein is thought to be involved in stereocilia organization and hair bundle formation. The gene is located in a region containing the human deafness loci DFNB12 and USH1D. Usher syndrome 1D and nonsyndromic autosomal recessive deafness DFNB12 are caused by allelic mutations of this cadherin-like gene. Upregulation of this gene may also be associated with breast cancer. Alternative splice variants encoding different isoforms have been described. [provided by RefSeq, May 2013]

Genome browser will be placed here

ACMG classification

Classification made for transcript

Verdict is Pathogenic. Variant got 10 ACMG points.

PP3
Splicing scoreres supports a deletorius effect: Scorers claiming Pathogenic: max_spliceai. No scorers claiming Uncertain. No scorers claiming Benign.
PP5
Variant 10-71779316-G-A is Pathogenic according to our data. Variant chr10-71779316-G-A is described in ClinVar as [Pathogenic]. Clinvar id is 4916.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr10-71779316-G-A is described in Lovd as [Pathogenic]. Variant chr10-71779316-G-A is described in Lovd as [Pathogenic]. Variant chr10-71779316-G-A is described in Lovd as [Likely_pathogenic].

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect #exon/exons MANE UniProt
CDH23NM_022124.6 linkuse as main transcriptc.5237G>A p.Arg1746Gln missense_variant 41/70 ENST00000224721.12

Ensembl

Gene Transcript HGVSc HGVSp Effect #exon/exons TSL MANE Appris UniProt
CDH23ENST00000224721.12 linkuse as main transcriptc.5237G>A p.Arg1746Gln missense_variant 41/705 NM_022124.6 P1Q9H251-1

Frequencies

GnomAD3 genomes
AF:
0.000145
AC:
22
AN:
152186
Hom.:
0
Cov.:
33
show subpopulations
Gnomad AFR
AF:
0.000193
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.00
Gnomad ASJ
AF:
0.00
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.00
Gnomad FIN
AF:
0.00
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.000206
Gnomad OTH
AF:
0.00
GnomAD3 exomes
AF:
0.0000682
AC:
17
AN:
249208
Hom.:
0
AF XY:
0.0000592
AC XY:
8
AN XY:
135214
show subpopulations
Gnomad AFR exome
AF:
0.0000646
Gnomad AMR exome
AF:
0.0000290
Gnomad ASJ exome
AF:
0.00
Gnomad EAS exome
AF:
0.00
Gnomad SAS exome
AF:
0.00
Gnomad FIN exome
AF:
0.00
Gnomad NFE exome
AF:
0.000133
Gnomad OTH exome
AF:
0.00
GnomAD4 exome
AF:
0.000161
AC:
236
AN:
1461678
Hom.:
0
Cov.:
31
AF XY:
0.000154
AC XY:
112
AN XY:
727122
show subpopulations
Gnomad4 AFR exome
AF:
0.000269
Gnomad4 AMR exome
AF:
0.0000224
Gnomad4 ASJ exome
AF:
0.00
Gnomad4 EAS exome
AF:
0.00
Gnomad4 SAS exome
AF:
0.0000116
Gnomad4 FIN exome
AF:
0.00
Gnomad4 NFE exome
AF:
0.000192
Gnomad4 OTH exome
AF:
0.000182
GnomAD4 genome
AF:
0.000145
AC:
22
AN:
152186
Hom.:
0
Cov.:
33
AF XY:
0.000134
AC XY:
10
AN XY:
74350
show subpopulations
Gnomad4 AFR
AF:
0.000193
Gnomad4 AMR
AF:
0.00
Gnomad4 ASJ
AF:
0.00
Gnomad4 EAS
AF:
0.00
Gnomad4 SAS
AF:
0.00
Gnomad4 FIN
AF:
0.00
Gnomad4 NFE
AF:
0.000206
Gnomad4 OTH
AF:
0.00
Alfa
AF:
0.000171
Hom.:
0
Bravo
AF:
0.000181
TwinsUK
AF:
0.000270
AC:
1
ALSPAC
AF:
0.00
AC:
0
ESP6500AA
AF:
0.00
AC:
0
ESP6500EA
AF:
0.000240
AC:
2
ExAC
AF:
0.0000662
AC:
8
EpiCase
AF:
0.000109
EpiControl
AF:
0.0000593

ClinVar

Significance: Pathogenic
Submissions summary: Pathogenic:16
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

not provided Pathogenic:5
Pathogenic, criteria provided, single submitterclinical testingGeneDxMar 21, 2023Published functional studies demonstrate a damaging effect; minigene functional splicing assay showed p.(R1746Q) causes aberrant splicing: a novel acceptor site is generated and exclusively used, resulting in in-frame exclusion of 51 bp, a predicted loss of 17 amino acid residues, including a DINDN Ca2+-binding motif, in EC17 (Becirovic et al., 2008); This variant is associated with the following publications: (PMID: 25468891, 28847902, 33089500, 12075507, 20613545, 25472526, 21940737, 32795431, 31980526, 32707200, 32037395, 35020051, 32991204, 11138009, 35186827, 18273900, 35076463, 35440622, 36056583) -
Pathogenic, criteria provided, single submitterclinical testingRevvity Omics, RevvityMay 18, 2021- -
Pathogenic, criteria provided, single submitterclinical testingInvitaeJan 28, 2024This sequence change replaces arginine, which is basic and polar, with glutamine, which is neutral and polar, at codon 1746 of the CDH23 protein (p.Arg1746Gln). RNA analysis indicates that this missense change induces altered splicing and likely results in the loss of 17 amino acid residue(s), but is expected to preserve the integrity of the reading-frame. This variant is present in population databases (rs111033270, gnomAD 0.01%). This missense change has been observed in individuals with Usher syndrome and autosomal recessive deafness (PMID: 11138009, 21940737, 25472526). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 4916). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt CDH23 protein function with a negative predictive value of 95%. Studies have shown that this missense change results in the activation of a cryptic splice site in exon 41 (PMID: 18273900, 21940737). For these reasons, this variant has been classified as Pathogenic. -
Pathogenic, criteria provided, single submitterclinical testingCeGaT Center for Human Genetics TuebingenMay 01, 2023CDH23: PM3:Very Strong, PM2, PP3, PS3:Supporting -
Pathogenic, criteria provided, single submitterclinical testingAthena DiagnosticsSep 03, 2020The frequency of this variant in the general population is consistent with pathogenicity (http://gnomad.broadinstitute.org). This variant has been reported to associate with Usher syndrome and nonsyndromic hearing loss (PMID: 11138009, 12075507, 21940737). Assessment of experimental evidence suggests this variant results in abnormal RNA splicing. Experiments show this variant creates a novel splice site, resulting in the in-frame deletion of 17 amino acids from the protein (PMID: 18273900). This variant segregates with disease in at least one family. In multiple individuals, this variant has been seen with a single recessive pathogenic variant in the same gene, suggesting this variant may also be pathogenic. -
Autosomal recessive nonsyndromic hearing loss 12;C1832845:Usher syndrome type 1D;C4539685:Pituitary adenoma 5, multiple types Pathogenic:1
Pathogenic, criteria provided, single submitterclinical testingFulgent Genetics, Fulgent GeneticsApr 28, 2022- -
CDH23-related disorder Pathogenic:1
Pathogenic, criteria provided, single submitterclinical testingIllumina Laboratory Services, IlluminaApr 27, 2017The CDH23 c.5237G>A (p.Arg1746Gln) missense variant has been identified in individuals with both Usher syndrome and nonsyndromic hearing loss who present with a range of phenotypes. The majority of the patients reported in the literature were diagnosed with Usher syndrome but some individuals with nonsyndromic hearing loss were also identified. Across a selection of the literature, the p.Arg1746Gln variant was reported in a homozygous state in six patients, in a compound heterozygous state in eight patients, in a heterozygous state in two patients in whom a second variant was not identified, and in a heterozygous state in one unaffected individual (Bolz et al. 2001; Astuto et al. 2002; Schultz et al. 2011; Zhao et al. 2015). Control data are not available for this variant, which is reported at a frequency of 0.00011 in the European (non-Finnish) population of the Exome Aggregation Consortium. Functional testing by Becirovic et al. (2008) indicated that the p.Arg1746Gln variant creates a novel splice acceptor site that results in an in-frame deletion of 51 base pairs and the exclusion of a calcium binding motif. Based on the collective evidence, the p.Arg1746Gln variant is classified as pathogenic for CDH23-related disorders. This variant was observed by ICSL as part of a predisposition screen in an ostensibly healthy population. -
Inborn genetic diseases Pathogenic:1
Pathogenic, criteria provided, single submitterclinical testingAmbry GeneticsJan 15, 2021The c.5237G>A (p.R1746Q) alteration is located in exon 41 (coding exon 40) of the CDH23 gene. This alteration results from a G to A substitution at nucleotide position 5237, causing the arginine (R) at amino acid position 1746 to be replaced by a glutamine (Q). Based on data from the Genome Aggregation Database (gnomAD), the CDH23 c.5237G>A alteration was observed in 0.0071% (20/280,608) total alleles studied, with a frequency of 0.013% (17/128,412) in the European (Non-Finnish) subpopulation. The c.5237G>A (p.R1746Q) alteration has been previously reported in either the homozygous or compound heterozygous state in multiple unrelated individuals with an Usher syndrome or deafness phenotype (Bolz, 2001; Schultz, 2011; Zhao, 2015) The p.R1746 amino acid is conserved in available vertebrate species. Functional analysis demonstrated that the p.R1746Q alteration creates a new cryptic splice acceptor site (Becirovic, 2008) The in silico prediction for the p.R1746Q alteration is inconclusive._x000D_ _x000D_ In silico splice site analysis predicts that this alteration may weaken the native splice acceptor site and will result in the creation or strengthening of a novel splice acceptor site. Based on the available evidence, this alteration is classified as pathogenic. -
Usher syndrome Pathogenic:1
Pathogenic, criteria provided, single submitterclinical testingWomen's Health and Genetics/Laboratory Corporation of America, LabCorpMar 03, 2022Variant summary: CDH23 c.5237G>A (p.Arg1746Gln) results in a conservative amino acid change in the encoded protein sequence. Four of five in-silico tools predict a benign effect of the variant on protein function. Several computational tools predict a significant impact on normal splicing: Four predict the variant creates a cryptic exonic alternate 3' splice acceptor site. At least one publication reports experimental evidence that this variant affects mRNA splicing resulting in the exclusion of 51-base pairs of exonic sequence consistent with the computational predictions (example, Becirovic_2008). The variant allele was found at a frequency of 6.8e-05 in 249208 control chromosomes. This frequency is not significantly higher than expected for a pathogenic variant in CDH23 causing Usher Syndrome (6.8e-05 vs 0.0032), allowing no conclusion about variant significance. c.5237G>A has been reported in the literature as homozygous and compound heterozygous genotypes in multiple individuals affected with hearing loss and/or Usher syndrome (example, Bolz_2001, Kannan-Sundhari_2020, Schultz_2011). These data indicate that the variant is very likely to be associated with disease. Ten clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. All laboratories classified the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. -
Pituitary adenoma 5, multiple types Pathogenic:1
Pathogenic, criteria provided, single submitterclinical testingBaylor GeneticsMar 27, 2024- -
Usher syndrome type 1 Pathogenic:1
Pathogenic, no assertion criteria providedclinical testingNatera, Inc.Sep 16, 2020- -
Usher syndrome type 1D Pathogenic:1
Pathogenic, no assertion criteria providedliterature onlyOMIMJan 01, 2001- -
Childhood onset hearing loss Pathogenic:1
Pathogenic, criteria provided, single submitterresearchNational Institute on Deafness and Communication Disorders, National Institutes of HealthJul 08, 2021PS1, PS3_moderate, PM2, PM3_very strong, PP3 (non REVEL) / Modifications from PMID: 30311386 for classification: The genetic causes of hearing loss have not yet been well characterized in the Yoruba population, and the information regarding variant MAF in this population is still limited, so we did not exclude any variant based on their "high" MAF. PP3 criteria was applied even if the REVEL score was below 0.7, if at least two of the pathogenicity prediction algorithms used predicted that the variant was damaging or likely damaging. -
Autosomal recessive nonsyndromic hearing loss 12 Pathogenic:1
Pathogenic, criteria provided, single submitterclinical testingVictorian Clinical Genetics Services, Murdoch Childrens Research InstituteJun 24, 2022Based on the classification scheme VCGS_Germline_v1.3.4, this variant is classified as Pathogenic. Following criteria are met: 0102 - Loss of function is a known mechanism of disease in this gene and is associated with deafness 12 (MIM#601386) and Usher syndrome, type 1D/F (MIM#601067). (I) 0106 - This gene is associated with autosomal recessive disease. (I) 0209 - Splice variant (non-canonical) proven to affect splicing of the transcript with uncertain effect on protein structure. Variant is predicted to result in a missense amino acid change from arginine to glutamine. Exon-trapping assay demonstrated aberrant splicing, predicting an in-frame deletion of 17 amino acids p.(Val1730_Arg1746del) (PMID: 18273900). (SP) 0251 - This variant is heterozygous. (I) 0304 - Variant is present in gnomAD (v3) <0.01 for a recessive condition (22 heterozygotes, 0 homozygotes). (SP) 0309 - An alternative amino acid change at the same position has been observed in gnomAD (v2) (72 heterozygotes, 0 homozygotes). (I) 0604 - Variant is not located in an established domain, motif, hotspot or informative constraint region. (I) 0801 - This variant has strong previous evidence of pathogenicity in unrelated individuals. This variant has been reported in greater than ten patients with Usher syndrome or non-syndromic hearing loss (Clinvar, PMID: 11138009, 12075507, 20613545, 21940737, 25468891, 35186827). (SP) 1208 - Inheritance information for this variant is not currently available in this individual. (I) Legend: (SP) - Supporting pathogenic, (I) - Information, (SB) - Supporting benign -
Rare genetic deafness Pathogenic:1
Pathogenic, criteria provided, single submitterclinical testingLaboratory for Molecular Medicine, Mass General Brigham Personalized MedicineAug 02, 2016The p.Arg1746Gln variant in CDH23 has been reported in >10 probands with Usher s yndrome and in 3 individuals with hearing loss (Bolz 2001, Astuto 2002, Schultz 2011, Bujakowska 2014, LMM data). Eight of these probands were compound heterozy gous for a second pathogenic variant, and two were homozygous. The variant has also segregated in 11 affected family members across 3 families (Bolz 2001, Schu ltz 2011, LMM data). This variant has been identified in 15/126682 European ch romosomes by the Genome Aggregation Database (gnomAd, http://gnomad.broadinstitu te.org; dbSNP rs111033270); however, its frequency is low enough to be consisten t with a recessive carrier frequency. In addition, mRNA studies revealed that t his variant affects splicing, causing in-frame skipping of 51 base pairs and sub sequently leading to a loss of 17 amino acids of the protein (Becirovic 2008). I n summary, this variant meets criteria to be classified as pathogenic for autoso mal recessive Usher syndrome based on case observations, segregation studies, an d functional evidence. ACMG/AMP Criteria applied: PM3_Very Strong, PP1_Strong, PM2, PS3_Moderate. -
Retinal dystrophy Pathogenic:1
Pathogenic, criteria provided, single submitterclinical testingBlueprint GeneticsJul 09, 2019- -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
0.077
BayesDel_addAF
Pathogenic
0.19
D
BayesDel_noAF
Pathogenic
0.27
CADD
Pathogenic
35
DANN
Pathogenic
1.0
DEOGEN2
Benign
0.0017
T;T
Eigen
Benign
0.046
Eigen_PC
Benign
0.18
FATHMM_MKL
Uncertain
0.97
D
LIST_S2
Uncertain
0.88
D;D
M_CAP
Benign
0.017
T
MetaRNN
Benign
0.36
T;T
MetaSVM
Benign
-0.99
T
MutationAssessor
Benign
0.025
.;N
MutationTaster
Benign
1.0
A
PrimateAI
Uncertain
0.50
T
REVEL
Uncertain
0.35
Sift4G
Uncertain
0.012
D;.
Polyphen
0.62
.;P
Vest4
0.54
MVP
0.73
ClinPred
0.71
D
GERP RS
4.9
Varity_R
0.28
gMVP
0.40

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.98
Details are displayed if max score is > 0.2
DS_AG_spliceai
0.98
Position offset: 2
DS_AL_spliceai
0.42
Position offset: -49

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

LitVar

Below is the list of publications found by LitVar. It may be empty.

Other links and lift over

dbSNP: rs111033270; hg19: chr10-73539073; COSMIC: COSV56464470; API